These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11758512)

  • 1. Side effects of antituberculosis treatment.
    de Maria A; Berardi M; Dignetti P; Ferrera L; Viassolo L; Canonica GW
    Thorax; 2001 Dec; 56(12):983. PubMed ID: 11758512
    [No Abstract]   [Full Text] [Related]  

  • 2. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
    Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
    Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazinamide-induced granulomatous hepatitis.
    Knobel B; Buyanowsky G; Dan M; Zaidel L
    J Clin Gastroenterol; 1997 Jun; 24(4):264-6. PubMed ID: 9252856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacology, toxicology and clinical use of pyrazinamide (author's transl)].
    Zierski M
    Prax Klin Pneumol; 1981 Dec; 35(12):1075-1105. PubMed ID: 6808484
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatotoxicity to different antituberculosis drug combinations.
    Aziz S; Agha F; Hassan R; Fairoz SA; Hassan K
    J Pak Med Assoc; 1990 Dec; 40(12):290-4. PubMed ID: 2126569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.
    Stout JE
    Expert Opin Drug Saf; 2004 May; 3(3):187-98. PubMed ID: 15155147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Side effects of antituberculosis therapy.
    Leung CC; Chan CK; Yew WW
    Am J Respir Crit Care Med; 2004 May; 169(10):1168-9; author reply 1169. PubMed ID: 15132966
    [No Abstract]   [Full Text] [Related]  

  • 8. [Short-term treatment of tuberculosis with and without pyrazinamide in the second phase (TA-80)].
    Farga V; Valenzuela P; Yañez A; Valenzuela MT; Scheel G; Mendoza F; Torres E; Icekson I; Grinspun M; Fernández M
    Rev Med Chil; 1983 Jul; 111(7):750-4. PubMed ID: 6680460
    [No Abstract]   [Full Text] [Related]  

  • 9. Treating pyrazinamide mono-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Pérez-Arellano CP; García-Toledo D
    Int J Tuberc Lung Dis; 2013 Sep; 17(9):1244-5. PubMed ID: 23928174
    [No Abstract]   [Full Text] [Related]  

  • 10. [Principles underlying the use of antituberculosis medication in children (author's transl)].
    Ollivier A; Besson-Leaud M
    Sem Hop; 1979 Oct 8-15; 55(33-34):1529-35. PubMed ID: 229564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):998-9. PubMed ID: 12455909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
    JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
    Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
    Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid biochemistry takes a stand against tuberculosis.
    Draper P
    Nat Med; 2000 Sep; 6(9):977-8. PubMed ID: 10973314
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of pulmonary tuberculosis in its current aspects].
    Gartmann JC
    Bibl Tuberc; 1965; 20():59-70. PubMed ID: 4291161
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in antituberculosis chemotherapy.
    Chan SL
    Xianggang Hu Li Za Zhi; 1979 Nov; (27):19-27. PubMed ID: 317480
    [No Abstract]   [Full Text] [Related]  

  • 19. Activity of pyrazinamide in the guinea pig model of tuberculosis.
    Mitchison DA
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5420. PubMed ID: 21075978
    [No Abstract]   [Full Text] [Related]  

  • 20. Short-course chemotherapy for pulmonary tuberculosis.
    Fox W; Mitchison DA
    Am Rev Respir Dis; 1975 Jun; 111(6):845-8 CONTD. PubMed ID: 49163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.